Investigator-assessed confirmed best overall response by Response Evaluation Criteria In Solid Tumors V.1.1
| All phase I SA patients (N=134) n (%) | All phase I combo patients (N=121) n (%) | |
| Best overall response | ||
| Complete response (CR) | 0 | 3 (2.5) |
| Partial response (PR) | 0 | 10 (8.3) |
| Stable disease (SD) | 32 (23.9) | 35 (28.9) |
| Progressive disease (PD) | 82 (61.2) | 55 (45.5) |
| Non-CR/non-PD (NCRNPD) | 2 (1.5) | 1 (0.8) |
| Unknown | 18 (13.4) | 17 (14.0) |
| Overall response rate (CR+PR) 90% CI | 0 (0.0 to 2.2) | 13 (10.7) (6.5 to 16.5) |
| Disease control rate (CR+PR+SD) 90% CI | 34 (25.4) (19.3 to 32.3) | 49 (40.5) (33.0 to 48.4) |
CI, confidence interval ; SA, single-agent.